

INFORMATION DISCLOSURE STATEMENT

(37 CFR 1.56, 1.97, and 1.98)

SHEET 1 OF 1



ATTORNEY DOCKET

25352-0003P8

APPLICATION NO.

09/9001442

APPLICANT(S)

Lawrence M. Kauvar et al.

FILING DATE

July 10, 2001

GROUP

1

TECH CENTER 1608 2900

JAN 30 2002

RECEIVED

U.S. PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)

FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
h	1	96/40205	12/1996	WO	
h	2	95/08563	03/1995	WO	
h	3	1 072 608 A1	01/2001	EP	

OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
h	4	Ciaccio P. J. et al, "Modulation of Detoxification Gene Expression In Human Colon HT29 Cells by Glutathione-S-Transferase Inhibitors", Molecular Pharmacology, Vol. 48, No. 4, October 1, 1995, pp. 639-647.
h	5	Morgan A. S. et al., "Isozyme-Specific Glutathione S-Transferase Inhibitors Potentiate Drug Sensitivity in Cultured Human Tumor Cell Lines", Cancer Chemotherapy and Pharmacology, Vol. 37, No. 4, 1996, pp. 363-370.
h	6	Schultz M et al., "Inhibitors Of Glutathione S-Transferases As Therapeutic Agents", Advanced Drug Delivery Reviews, Vol. 26, No. 2/03, July 1, 1997, pp. 91-104.

EXAMINER'S SIGNATURE

Khu

DATE CONSIDERED

3/04

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).